Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Soroka University Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Soroka University Medical Center
ClinicalTrials.gov Identifier:
NCT00420394
First received: January 9, 2007
Last updated: June 19, 2007
Last verified: January 2007
  Purpose

Rationale: Adjuvant chemoradiation considered as standard of care after curative surgery for adenocarcinoma of stomach and gastroesophageal cancer. Preoperative chemotherapy in the in locally advanced gastric cancer results in significant tumoral downstaging with improved rate of curative resections.

Purpose: To evaluate feasibility and safety of combination of preoperative chemotherapy and postoperative chemoradiation for locally advanced adenocarcinoma of stomach and gastroesophageal cancer


Condition Intervention Phase
Stomach Neoplasms
Procedure: Chemotherapy
Procedure: surgery
Procedure: radiotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Preoperative Chemotherapy and Postoperative Chemo-Radiation for Newly Diagnosed, Potentially Resectable Gastric Cancer

Resource links provided by NLM:


Further study details as provided by Soroka University Medical Center:

Primary Outcome Measures:
  • Feasibility of the study regimen.

Secondary Outcome Measures:
  • Rate of R0 resection following chemotherapy.
  • Morbidity and mortality of surgery following chemotherapy.
  • Overall and progression free survival following the study treatment plan

Estimated Enrollment: 30
Study Start Date: April 2007
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed primary adenocarcinoma, poorly differentiated carcinoma, or carcinoma not otherwise specified, of stomach or gastro-esophageal junction.
  2. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3
  3. Disease must be clinically limited to the stomach or GEJ.
  4. Pre-treatment Port-a-Cath insertion obligatory
  5. No prior chemotherapy.
  6. No prior radiotherapy.
  7. Patients must be surgical candidates as determined by the treating surgeon.
  8. Adequate organ function defined as:
  9. Patients must have an ECOG Performance Status < 1.
  10. Patients must be able to sign the informed consent document.

Exclusion Criteria:

  1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy, endoscopic ultrasound and CT scanning.
  2. Patients with primary carcinomas of the esophagus.
  3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past 5 years, or prior esophageal or gastric surgery.
  4. Patients with evidence of metastatic disease are not eligible.
  5. New York Heart Association Class III or IV heart disease.
  6. Severe co-morbid conditions or nonmalignant illness whose control may be jeopardized by complications of the study treatment.
  7. Pregnant or lactating women or men unable or unwilling to practice contraception are excluded.
  8. Any history of prior malignancy (other than non-melanoma skin cancer, in-situ cervical cancer, or superficial transitional cell bladder cancer).
  9. Clinically significant hearing loss.
  10. Patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication.
  11. Patients who cannot fully comprehend the therapeutic implications of the protocol or comply with its requirements.
  12. Patients with any medical or psychiatric condition or disease which, in the investigator’s judgment, would make the patient inappropriate for entry into this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00420394

Contacts
Contact: Margarita Tokar, MD +972-8-6400768 Ritato@clalit.org.il
Contact: Dmitri Bobilev, MD +972-8-6400295 dmitrib@bgu.ac.il

Locations
Israel
Soroka University Medical Center,Oncology Center Recruiting
Beer-sheva, Israel
Contact: margarita Tokar, MD    +972-86400768    ritato@clalit.org.il   
Sub-Investigator: Konstantin Lavrenkov, MD         
Sponsors and Collaborators
Soroka University Medical Center
Investigators
Study Chair: Margarita Tokar, MD Soroka University Medical Center and Ben-Gurion University of the Negev
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00420394     History of Changes
Other Study ID Numbers: SOR446006ctil
Study First Received: January 9, 2007
Last Updated: June 19, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Soroka University Medical Center:
Neoadjuvant chemotherapy
Adjuvant chemoradiotherapy
Adenocarcinoma of stomach and gastroesophageal junction

Additional relevant MeSH terms:
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Stomach Diseases

ClinicalTrials.gov processed this record on November 25, 2014